Getting people to change their mentality when it comes to their health is a very difficult prospect, but one that researchers attempted to tackle as part of the Aligning Forces for Quality (AF4Q), explained Donald M. Berwick, MD, MPP, president emeritus and senior fellow of the Institute for Healthcare Improvement. Berwick served as the special guest editor for the supplement publishing results of the AF4Q initiative.
Getting people to change their mentality when it comes to their health is a very difficult prospect, but one that researchers attempted to tackle as part of the Aligning Forces for Quality (AF4Q), explained Donald M. Berwick, MD, MPP, president emeritus and senior fellow of the Institute for Healthcare Improvement. Berwick served as the special guest editor for the supplement publishing results of the AF4Q initiative.
What can be done to bring the lessons of AF4Q into the broader debate this election season?
The lessons of AF4Q, they're technically complicated lessons. The papers that are being assembled in this special issue that's reporting out of this, they're brilliant papers. They're going to be landmarks. But they're really specialty oriented.
We really still need a way to help busy laypeople, who have a stake in their communities but have many, many things on their minds, to be able to grasp what it means to align for health. What their responsibility is, how to act cooperatively. That's unsolved. And, indeed, one of the lessons learned in AF4Q is how difficult that is.
The attention of the public is a very limited resource and I'd say the challenge in an election year, and any year, is to bridge between the technical understandings of how we can really achieve better health and the day-to-day mentality of a very busy public. That's unsolved. We're not there yet.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More